Dietmar W. Siemann - Publications

Affiliations: 
University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Pharmacology, Oncology, Animal Physiology Biology, Cell Biology

58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lønbro S, Wiggins JM, Wittenborn T, Elming PB, Rice L, Pampo C, Lee JA, Siemann DW, Horsman MR. Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running. Plos One. 14: e0215584. PMID 31050686 DOI: 10.1371/journal.pone.0215584  0.84
2018 Bohórquez AC, Unni M, Belsare S, Chiu Lam A, Rice L, Pampo C, Siemann DW, Rinaldi C. STABILITY AND MOBILITY OF MAGNETIC NANOPARTICLES IN BIOLOGICAL ENVIRONMENTS DETERMINED FROM DYNAMIC MAGNETIC SUSCEPTIBILITY MEASUREMENTS. Bioconjugate Chemistry. PMID 30011185 DOI: 10.1021/acs.bioconjchem.8b00419  0.84
2016 Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, Chang LJ, Lu J. Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. The Journal of Clinical Investigation. PMID 27721239 DOI: 10.1172/JCI86623  0.84
2016 Bosse RC, Wasserstrom B, Meacham A, Wise E, Drusbosky L, Walter GA, Chaplin DA, Siemann DW, Purich DL, Cogle CR. Chemosensitizing AML cells by Targeting Bone Marrow Endothelial Cells. Experimental Hematology. PMID 26898708 DOI: 10.1016/j.exphem.2016.02.003  0.96
2016 Sudhan DR, Pampo C, Rice L, Siemann DW. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. International Journal of Cancer. 138: 2665-77. PMID 26757413 DOI: 10.1002/ijc.29992  0.84
2015 Parker EN, Song J, Kishore Kumar GD, Odutola SO, Chavarria GE, Charlton-Sevcik AK, Strecker TE, Barnes AL, Sudhan DR, Wittenborn TR, Siemann DW, Horsman MR, Chaplin DJ, Trawick ML, Pinney KG. Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorganic & Medicinal Chemistry. PMID 26462052 DOI: 10.1016/j.bmc.2015.09.036  0.96
2015 Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacology & Therapeutics. 153: 107-24. PMID 26073310 DOI: 10.1016/j.pharmthera.2015.06.006  0.32
2015 Pham K, Luo D, Siemann DW, Law BK, Reynolds BA, Hothi P, Foltz G, Harrison JK. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Letters. 360: 60-7. PMID 25676691 DOI: 10.1016/j.canlet.2015.02.005  0.96
2014 Biel NM, Lee JA, Sorg BS, Siemann DW. Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis. Vascular Cell. 6: 17. PMID 25101168 DOI: 10.1186/2045-824X-6-17  0.96
2014 Lee JA, Biel NM, Kozikowski RT, Siemann DW, Sorg BS. In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. Biomedical Optics Express. 5: 1965-79. PMID 24940553 DOI: 10.1364/BOE.5.001965  0.96
2014 McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. Journal of the National Cancer Institute. 106: dju036. PMID 24627275 DOI: 10.1093/jnci/dju036  0.96
2014 Magdoom KN, Pishko GL, Rice L, Pampo C, Siemann DW, Sarntinoranont M. MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor. Plos One. 9: e89594. PMID 24619021 DOI: 10.1371/journal.pone.0089594  0.96
2014 Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anti-Cancer Drugs. 25: 332-9. PMID 24304691 DOI: 10.1097/CAD.0000000000000061  0.96
2013 McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ. Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. Journal of Applied Physiology (Bethesda, Md. : 1985). 115: 1846-54. PMID 24177690 DOI: 10.1152/japplphysiol.00949.2013  0.96
2013 Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, Chang MN, Neal D, Siemann DW. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. American Journal of Veterinary Research. 74: 771-8. PMID 23627391 DOI: 10.2460/ajvr.74.5.771  0.96
2013 Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 121: 707-15. PMID 23212515 DOI: 10.1182/blood-2012-05-433045  0.96
2013 Sefah K, Bae KM, Phillips JA, Siemann DW, Su Z, McClellan S, Vieweg J, Tan W. Cell-based selection provides novel molecular probes for cancer stem cells. International Journal of Cancer. Journal International Du Cancer. 132: 2578-88. PMID 23150432 DOI: 10.1002/ijc.27936  0.96
2012 Siemann DW, Dong M, Pampo C, Shi W. Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell and Tissue Research. 349: 541-50. PMID 22526632 DOI: 10.1007/s00441-012-1415-7  1
2012 Dai Y, Bae K, Pampo C, Siemann DW. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clinical & Experimental Metastasis. 29: 253-61. PMID 22286523 DOI: 10.1007/s10585-011-9447-z  0.84
2012 Rice L, Lepler S, Pampo C, Siemann DW. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clinical & Experimental Metastasis. 29: 133-42. PMID 22130962 DOI: 10.1007/s10585-011-9436-2  0.84
2011 Tang M, Chen B, Lin T, Li Z, Pardo C, Pampo C, Chen J, Lien CL, Wu L, Ai L, Wang H, Yao K, Oh SP, Seto E, Smith LE, ... Siemann DW, et al. Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proceedings of the National Academy of Sciences of the United States of America. 108: 15231-6. PMID 21896759 DOI: 10.1073/pnas.1104662108  0.96
2011 Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology. 87: 1126-34. PMID 21815749 DOI: 10.3109/09553002.2011.605418  0.32
2011 Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvascular Research. 81: 44-51. PMID 20974154 DOI: 10.1016/j.mvr.2010.10.003  0.84
2010 Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Research. 30: 4405-13. PMID 21115886  0.84
2010 Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 116: 1539-47. PMID 20472832 DOI: 10.1182/blood-2009-06-230474  0.96
2010 Wankhede M, Dedeugd C, Siemann DW, Sorg BS. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. Oncology Reports. 23: 685-92. PMID 20127007 DOI: 10.3892/or-00000685  0.96
2009 Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 114: 4310-9. PMID 19717647 DOI: 10.1182/blood-2009-03-211342  0.96
2009 Siemann DW, Norris CM, Ryan A, Shi W. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Research. 29: 1987-92. PMID 19528456  0.96
2009 Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion On Investigational Drugs. 18: 189-97. PMID 19236265 DOI: 10.1517/13543780802691068  0.96
2009 Siemann DW, Brazelle WD, Jürgensmeier JM. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. International Journal of Radiation Oncology, Biology, Physics. 73: 897-903. PMID 19215823 DOI: 10.1016/j.ijrobp.2008.10.031  0.8
2009 Coomer AR, Farese JP, Milner R, Taylor D, Salute ME, Rajon DA, Bova FJ, Siemann DW. Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. American Journal of Veterinary Research. 70: 127-33. PMID 19119958 DOI: 10.2460/ajvr.70.1.127  0.96
2009 Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell and Tissue Research. 335: 241-8. PMID 18752004 DOI: 10.1007/s00441-008-0646-0  0.32
2008 Fitzpatrick CL, Farese JP, Milner RJ, Salute ME, Rajon DA, Morris CG, Bova FJ, Lurie DM, Siemann DW. Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. American Journal of Veterinary Research. 69: 1197-202. PMID 18764694 DOI: 10.2460/ajvr.69.9.1197  0.96
2008 Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Research. 28: 2027-31. PMID 18751370  1
2007 Siemann DW, Chaplin DJ. An update on the clinical development of drugs to disable tumor vasculature. Expert Opinion On Drug Discovery. 2: 1357-67. PMID 23484531 DOI: 10.1517/17460441.2.10.1357  0.96
2006 Norris CM, Shi W, Siemann DW. Impact of VEGF expression on the physiological characteristics of clonal cell lines. In Vivo (Athens, Greece). 20: 815-21. PMID 17203773  0.96
2006 Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Research. 66: 11520-39. PMID 17178843 DOI: 10.1158/0008-5472.CAN-06-2848  0.32
2006 Shi W, Siemann DW. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Research. 26: 3445-53. PMID 17094465  1
2006 Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Current Opinion in Investigational Drugs (London, England : 2000). 7: 522-8. PMID 16784022  0.96
2006 Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 65: 836-41. PMID 16751064 DOI: 10.1016/j.ijrobp.2006.02.023  1
2006 Teschendorf C, Warrington KH, Shi W, Siemann DW, Muzyczka N. Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer Research. 26: 311-7. PMID 16475712  0.96
2005 Shi W, Siemann DW. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Research. 25: 3899-904. PMID 16309177  1
2005 Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo (Athens, Greece). 19: 1045-50. PMID 16277020  1
2005 Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 416-20. PMID 15701823  0.32
2004 Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. International Journal of Radiation Oncology, Biology, Physics. 60: 1233-40. PMID 15519796 DOI: 10.1016/j.ijrobp.2004.08.002  1
2004 Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 100: 2491-9. PMID 15197790 DOI: 10.1002/cncr.20299  0.96
2004 Siemann DW, Horsman MR. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Review of Anticancer Therapy. 4: 321-7. PMID 15056061 DOI: 10.1586/14737140.4.2.321  0.32
2004 Shi W, Siemann DW. Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach. Anticancer Research. 24: 213-8. PMID 15015599  1
2003 Coleman CN, Stone HB, Alexander GA, Barcellos-Hoff MH, Bedford JS, Bristow RG, Dynlacht JR, Fuks Z, Gorelic LS, Hill RP, Joiner MC, Liu FF, McBride WH, McKenna WG, Powell SN, ... ... Siemann DW, et al. Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiation Research. 160: 729-37. PMID 14640790 DOI: 10.1667/RR3096  0.96
2003 Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 66: 1-9. PMID 12559515 DOI: 10.1016/S0167-8140(02)00280-3  0.96
2003 Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy Seminars in Radiation Oncology. 13: 53-61. PMID 12520464 DOI: 10.1053/srao.2003.50005  0.96
2002 Teschendorf C, Warrington KH, Siemann DW, Muzyczka N. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Research. 22: 3325-30. PMID 12530082  0.96
2002 Siemann DW, Horsman MR. Enhancement of radiation therapy by vascular targeting agents. Current Opinion in Investigational Drugs (London, England : 2000). 3: 1660-5. PMID 12476970  0.32
2002 Shi W, Siemann DW. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor British Journal of Cancer. 87: 119-126. PMID 12085267 DOI: 10.1038/sj.bjc.6600416  0.96
2002 Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Therapy. 9: 513-21. PMID 12032662 DOI: 10.1038/sj.cgt.7700463  0.96
2002 Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. International Journal of Cancer. Journal International Du Cancer. 99: 1-6. PMID 11948484 DOI: 10.1002/ijc.10316  0.56
2000 Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 57: 5-12. PMID 11033183  0.6
1998 Warrington KH, Teschendorf C, Cao L, Muzyczka N, Siemann DW. Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. International Journal of Radiation Oncology, Biology, Physics. 42: 909-12. PMID 9845120 DOI: 10.1016/S0360-3016(98)00357-5  0.96
Show low-probability matches.